Navigation Links
Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
Date:5/29/2009

PITTSBURGH, May 29 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Montelukast Sodium Tablets, 10 mg (base).

Montelukast Sodium Tablets are the generic version of Merck and Co.'s Singulair(R), which had total U.S. sales of approximately $2.6 billion for the 12 months ending March 31 for the same strength, according to IMS Health. This product is indicated for asthma and allergy treatment.

Currently, Mylan has 117 ANDAs pending FDA approval representing $82.1 billion in annual brand sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, which represent $16.7 billion in annual brand sales, according to IMS Health.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Mylans Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
2. Mylans Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
3. Mylan Confirms Four First-to-File Challenges
4. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
5. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
6. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
7. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
8. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
9. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
10. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
11. Mylan Announces Final FDA Approval for Ropinirole Hydrochloride Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)...  Eurofins Genomics today announced the expansion of its ... receive their primers in a shorter turnaround time, without ... with other providers. Express oligos are available for anyone ... no additional fee. Researchers use the oligos ... sequencing, genotyping, site-directed mutagenesis, and cloning. Often, they are ...
(Date:1/13/2017)... Research and Markets has announced the addition of the "Global ... ... CAGR of 16.83% during the period 2017-2021. The report ... market for 2017-2021. To calculate the market size, the report considers the ... also includes a a discussion of the key vendors operating in this ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... SUCCESS , VTI, Vertebral Technologies, Inc., announces the successful outcome of the ... Since September 2016, VTI (Vertebral Technologies, Inc.) has partnered with Mexico-based medical ...
(Date:1/12/2017)... (PRWEB) , ... January 12, 2017 , ... ... to targeted treatments, 26-year-old Lisa Rosendahl’s doctors gave her only a few months ... a new drug combination that has stabilized Rosendahl’s disease and increased both the ...
Breaking Biology Technology:
(Date:12/6/2016)... N.C. , Dec. 6, 2016 Valencell ... announced today it has seen a third consecutive year ... biometric sensor technology in 2016 with a 360 percent ... last year. This increase was driven by sales of ... as robust interest in its technology for hearables for ...
(Date:12/5/2016)...  The Office of Justice Programs, National Institute ... Enhance or Replace Medico Legal Autopsies?" on NIJ.gov.  ... replacing forensic autopsies with postmortem X-ray computed tomography, ... response to recommendations made by The National Academy ... as a potential component of medicolegal death investigations. ...
(Date:12/2/2016)... , Dec. 1, 2016   SoftServe ... announced BioLock , an electrocardiogram (ECG) biosensor ... monitoring, a key IoT asset. The smart system ... a vehicle,s steering wheel and mobile devices to ... touch. As vehicle technology advances, so ...
Breaking Biology News(10 mins):